Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Jun;97(24):e10717.
doi: 10.1097/MD.0000000000010717.

Paraneoplastic cerebellar degeneration associated with cerebellar hypermetabolism: Case report

Affiliations
Case Reports

Paraneoplastic cerebellar degeneration associated with cerebellar hypermetabolism: Case report

Ammar Taha Abdullah Abdulaziz et al. Medicine (Baltimore). 2018 Jun.

Abstract

Rationale: Paraneoplastic cerebellar degeneration (PCD) is an immune-mediated neurological deficit affecting the cerebellum. Anti-Yo antibody positive PCD is a rare occurrence most likely associated with gynecologic or breast malignancies. The identification of the underlying tumor is a diagnostic challenge in many of these patients.

Patient concerns: We present a 68-year-old woman with acute symptoms of PCD as a first sign of underlying occult malignancy. Further investigation revealed a positive anti-Yo antibody. Although brain magnetic resonance imaging (MRI) was unremarkable, positron emission tomography (PET)/computed tomography (CT) revealed intense hypermetabolism of cerebellum and diffused hypometabolism in the rest of brain. On 1-year follow-up, despite the primary malignancy is still unknown, her symptoms improved significantly after immunotherapy.

Diagnoses: Paraneoplastic cerebellar degeneration.

Interventions: The patient was given IV methylprednisolone 500 mg once a day for 5 consecutive days, followed by oral prednisone 60 mg once a day for 3 months.

Outcomes: The patient's symptoms were gradually improved during the hospitalization period. On one year follow up, she was able to walk independently and perform some simple tasks.

Lessons: Cerebellar hypermetabolism in PCD suspected patients may help confirming the diagnosis in an earlier stage and may predict a better outcome after immunotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no financial or other conflicts of interest.

Figures

Figure 1
Figure 1
Transversal cranial MRI reveals no abnormal finding (A, B); Immunohistochemistry of right axillary lymph nodes reveals metastatic cancer cells from unknown origin (C).
Figure 2
Figure 2
PET/CT images show intense metabolic activity in the cerebellum associated with hypometabolism in the rest of brain (A, B); Right-sided axillary lymph nodes hypermetabolism with the absence of breast tissue hypermetabolism (C); significant metabolic activity in the intestine (D).
Figure 3
Figure 3
FDG-PET (A) reveals abnormal hot spots in the pelvic (black arrow) and axillary (blue arrow) regions. Coronal PET-CT (B) demonstrates abnormal increased glucose utilization in 2 different regions (white arrow indicates right axillary lymph node hypermetabolism; green arrow indicates significant intestinal hypermetabolism).

Similar articles

Cited by

References

    1. Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol 2008;7:327–40. - PMC - PubMed
    1. Peterson K, Rosenblum MK, Kotanides H, et al. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 1992;42:1931–7. - PubMed
    1. Shams’ili S, Grefkens J, de Leeuw B, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain 2003;126:1409–18. - PubMed
    1. Lorusso L, Hart IK, Giometto B, et al. Immunological features of neurological paraneoplastic syndromes. Int J Immunopathol Pharmacol 2004;17:135–44. - PubMed
    1. Rojas I, Graus F, Keime-Guibert F, et al. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology 2000;55:713–5. - PubMed

Publication types

MeSH terms